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BACKGROUND: Little is known about the patterns of care relating to the diagnosis of chronic lymphocytic leukemia
(CLL), including the use of modern diagnostic techniques such as flow cytometry. METHODS: The authors used the
SEER-Medicare database to identify subjects diagnosed with CLL from 1992 to 2002 and defined diagnostic delay as
present when the number of days between the first claim for a CLL-associated sign or symptom and SEER diagnosis
date met or exceeded the median for the sample. The authors then used logistic regression to estimate the likelihood
of delay and Cox regression to examine survival. RESULTS: For the 5086 patients analyzed, the median time between
sign or symptom and CLL diagnosis was 63 days (interquartile range [IQR] ¼ 0-251). Predictors of delay included
age 75 (OR 1.45 [1.27-1.65]), female gender (OR 1.22 [1.07-1.39]), urban residence (OR 1.46 [1.19 to 1.79]), 1 comor-
bidities (OR 2.83 [2.45-3.28]) and care in a teaching hospital (OR 1.20 [1.05-1.38]). Delayed diagnosis was not associ-
ated with survival (HR 1.11 [0.99-1.25]), but receipt of flow cytometry within thirty days before or after diagnosis was
(HR 0.84 [0.76-0.91]). CONCLUSIONS: Sociodemographic characteristics affect diagnostic delay for CLL, although
delay does not seem to impact mortality. In contrast, receipt of flow cytometry near the time of diagnosis is associ-
ated with improved survival. Cancer 2011;117:1470–7. VC 2010 American Cancer Society.
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Delays in referral and diagnosis may negatively affect outcomes associated with many childhood malignancies and
adult solid tumors.1-4 In contrast, little research has examined the relationship between diagnostic delay and outcomes for
adult hematologic malignancies,5 despite improved techniques for pathologic diagnosis, staging, prognostication, and
therapy. Such innovations may offer significant benefits for those who are referred, diagnosed, and treated in a timely
mannersuch has been demonstrated for younger patients with acute myelogenous leukemia6even for patients with
indolent malignancies such as chronic lymphocytic leukemia (CLL). Indeed, timeliness of care was identified as 1 of 6
aims of healthcare quality improvement in the Institute of Medicine’s Crossing the Quality Chasm report.7 Given that CLL
is the most common type of leukemia,8 even small differences in outcomes driven by diagnostic delays have the potential
for significant societal impact.
CLL is a disease of older adults. It has a median age of diagnosis in the United States of 72 years, with 89% of
patients initially diagnosed at or above the age of 65 years.9 Perhaps because of its indolence and predilection for the el-
derly, many cases of CLL are identified incidentally or diagnosed presumptively in physician’s offices without pathologic
DOI: 10.1002/cncr.25655, Received: March 15, 2010; Revised: July 11, 2010; Accepted: August 9, 2010, Published online November 8, 2010 in Wiley Online
Library (wileyonlinelibrary.com)
Corresponding author: Gregory A. Abel, MD, MPH, MD, MPH, Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, 44 Binney Street, Smith
271, Boston, MA 02115; Fax: (617) 632-2270; gregory_abel@dfci.harvard.edu
1Division of Nursing Business and Health System, University of Michigan School of Nursing, Ann Arbor, Michigan; 2Institute for Clinical Evaluative Sciences and
University of Toronto, Toronto, Ontario, Canada; 3Division of Hematology/Oncology, Children’s Hospital, Boston, Massachusetts; 4Division of Hematologic Malig-
nancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 5Center for Outcomes and Policy Research, Department of Medi-
cal Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; 6Department of Surgery, Brigham and Womens’ Hospital, Boston, Massachusetts; 7Division of
Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
Findings from this paper were presented at the 2008 American Society of Hematology Annual Meeting.
We thank Dr. David Ronis for statistical consultation. This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the
sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Devel-
opment and Information, Centers for Medicare and Medicaid Services; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End
Results (SEER) program tumor registries in the creation of the SEER-Medicare database.
1470 Cancer April 1, 2011
Original Article
confirmation. Moreover, even when a pathologist is
involved, it is difficult to distinguish CLL from a morpho-
logically similar disease such as mantle cell lymphoma.8
Because of its utility for definitive diagnosis,10-11 confirm-
atory flow cytometry has been increasingly recommended
as a baseline test—and a measure of quality of care—for
patients with CLL. For example, the National Compre-
hensive Cancer Network has long recommended baseline
immunophenotyping on bone marrow or peripheral
blood with flow cytometry for all patients with CLL.12 In
addition, in 2008, the National Quality Forum working
with the American Society of Hematology and the Ameri-
can Medical Association’s Physician Consortium for Per-
formance Improvement endorsed baseline flow cytometry
for all patients with CLL as a quality of care standard.13
It is not currently known what clinical and sociode-
mographic factors predict delays in CLL diagnosis and,
given its mostly indolent nature, whether delays have any
effect on survival. In this context, we sought to estimate
the time between CLL-associated signs or symptoms and
diagnosis and to assess several covariates of delay. We also
aimed to understand the correlates of receipt of baseline
flow cytometry and to evaluate the effect that delays in
diagnosis and receipt of flow cytometry might have on
survival after a CLL diagnosis.
MATERIALS AND METHODS
Our overall analytic approach has been previously pub-
lished.14 Below, we briefly review data sources, sample
selection, measures, and data analysis.
Sources of Data
The Surveillance, Epidemiology, and End Results
(SEER)–Medicare dataset was used to identify patients
diagnosed with CLL. The SEER-Medicare dataset com-
bines cancer registry information with complete claims
data for adults age 65 years and older who are enrolled in
traditional Medicare Parts A and B.15 The analysis sample
contained patients diagnosed with CLL between February
1, 1992 and December 31, 2002. The 16 registries in this
dataset cover a representative sample of 26% of the popu-
lation of the United States and are oversampled to capture
racial and ethnic minorities.32,33 Participating tumor
registries are estimated to capture approximately 97% of
incident cases reported by hospitals.16 The Dana-Farber
Cancer Institute Institutional Review Board granted
exempt review status to our study protocol. The protocol
was also reviewed by the institutional review board at the
Centers for Disease Control, and a signed data-use agree-
ment was executed with the SEER-Medicare coordinating
center.
Patient Sample
By using the SEER registry data, we identified patients
with CLL diagnoses that were confirmed by pathologic or
laboratory findings. Patients with multiple cancers were
eligible only when CLL was the first cancer diagnosed.
Because the availability of complete claims was required
to measure healthcare utilization with accuracy, we
applied several additional selection criteria: the SEER di-
agnosis date of CLL (henceforth defined as diagnosis
date) had to be on, or after, the patient’s date of Medicare
enrollment; patients had to survive 6 or more months af-
ter diagnosis; and patients had to be continuously enrolled
in both Part A and Part B Medicare for the year preceding
CLL diagnosis through at least 6 months after diagnosis.
We identified 5831 patients in the participating registries
who were diagnosed with CLL between 1992 and 2002
and who met eligibility criteria. Of these, we excluded
745 patients based on the following: diagnosis at autopsy,
eligible for Medicare because of end-stage renal disease or
disability, and participation in health maintenance organ-
izations during the study period. The final analytic sample
consisted of 5086 patients.
Study Variables
Patient Characteristics
We used the Patient Entitlement and Diagnosis
Summary File (PEDSF) to measure patient characteris-
tics, including age, sex, race/ethnicity, geographic region
of residence (Northeast, Midwest, South, and West), and
residence in an urban versus rural area (as defined by resi-
dence in a metropolitan statistical area). Medicare inpa-
tient (MEDPAR), outpatient (OUTSAF), and physician
(NCH) files were used to construct a modified Charlson
comorbidity score for all patients by reviewing claims for
the year before the SEER diagnosis date.17 Comorbidity
was identified by using methods reported in previously
published studies.15,18
Signs, Symptoms, and Diagnostic Procedures
After literature review and consultation with clinical
experts, we matched possible signs and symptoms of CLL
to diagnoses and procedures from the claims data by using
International Classification of Diseases, 9th edition
(ICD-9) and Current Procedural Terminology (CPT)
codes. (The frequencies of these diagnoses and procedures
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are reported in the Results section of this article; a list of
the specific codes used is available from the authors upon
request.) We created dichotomous measures to identify
the presence or absence of claims for these signs and symp-
toms for 1 year preceding the SEER diagnosis date.
CLL diagnosis and delay
We measured the number of days between the first
claim for a CLL sign or symptom and the SEER CLL diag-
nosis date. By using a similar approach to our prior research
on delays,14 we defined diagnostic delay as occurring in
patients whose time between sign or symptom claim and
diagnosis date exceeded the median number of days for the
sample. SEER provides only month and year for diagnosis.
However, researchers have identified that SEER diagnosis
month and year are concordant with clinical diagnosis dates
found in claims within a window of 30 days.19 Accord-
ingly, we set diagnosis dates to the 15th day of the SEER-
recorded month and year for all subjects. In our analyses
described below, we then reran our analytic models with
adjusted calculations of the time between diagnosis dates
and dates of signs, symptoms, or diagnostic procedures,
using30 days as a conservative estimate.
Processes of care
ICD-9 diagnosis, CPT procedure, and Health Care
Procedure Coding System (HCPCS) codes identified in
MEDPAR, OutSAF, and NCH files were used to measure
the receipt of systemic chemotherapy within the first 6
months of diagnosis (a list of these codes is available from
the author). Patient claims for inpatient services in MED-
PAR files were reviewed to identify whether patients were
treated in teaching hospitals (as defined by the Medicare
Provider of Service survey) in the year preceding diagno-
sis. We also identified patients who had a claim for flow
cytometry performed within 30 days before or after their
CLL diagnosis date.
Data Analysis
We used SAS 9.1.3 (SAS Institute, Cary, NC) for all anal-
yses. Coefficients obtained from logistic regression models
were expressed as odds ratios with 95% confidence inter-
vals. Coefficients from Cox regression models were
reported as hazard ratios with corresponding 95% confi-
dence intervals.
Examination of Delays
For the 4081 patients who had a claim for a sign or
symptom related to CLL occurring before diagnosis, we
used logistic regression models to estimate the effect of
patient characteristics on the likelihood of delay as defined
above. Patient demographics, comorbidities, healthcare
utilization in the prior year, and initial source of diagnosis
were included in the model.
Use and Predictors of Flow Cytometry
The Cochran-Armitage test for trend was used to
examine the proportion of patients who received flow
cytometry in each year of the study period. A multivariate
logistic regression model estimated the likelihood of
undergoing flow cytometry analysis within 30 days of
CLL diagnosis. Independent variables included the
patient characteristics described above.
Examination of Survival
Cox regression was used to estimate the impact of
diagnosis delays and receipt of flow cytometry within 30
days of CLL diagnosis on overall survival.20 Covariate
selection was accomplished by including those variables
significantly associated with delay in our prior models
plus sociodemographic factors.
Sensitivity Analyses
There is no accepted standard to define diagnostic
delay. We, thus, examined diagnostic delay by using a va-
riety of additional measurement approaches, including
treating it as a continuous measure, considering diagnoses
that exceeded the mean (as opposed to the median value
as above), and analyzing tertiles and quartiles of median
time to diagnosis. In addition, we re-estimated a Cox
model with empirically derived independent variables.
This was accomplished by including delay in all models
and adding each independent variable in turn to examine
for significant effects. Variables were retained at P < .05,
and first-order interaction terms were examined and
retained with similar criteria.
RESULTS
The study inclusion criteria identified 5086 patients for
the analysis of receipt of flow cytometry and of survival
(full sample). Because not all patients had a claim for a
sign or symptom before diagnosis, 4081 (80%) were
included in the analysis of delays (delay sample). Table 1
shows the characteristics of study patients by sample. The
median age for both samples was 75 years; approximately
30% of patients in both had at least 1 comorbidity as
measured by the modified Charlson Comorbidity Index.
Chi-square and Student t tests revealed no significant
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differences in patient characteristics between the full and
the delay samples (results not shown).
Table 2 shows the presenting signs, symptoms, and
diagnostic tests reported in the full sample for the year
preceding the diagnosis date. The most common Medi-
care claim was for infection (32.2%), followed by
lymphocytosis (28.7%), anemia (23.9%), and fatigue
(16.6%). Just over half had a complete blood count per-
formed during the year before diagnosis.
In the delay sample (n ¼ 4081), the mean time
between first sign or symptom and CLL diagnosis was
121.5 days, with a median of 63 days (interquartile range
[IQR], 0 to 251 days). Results were adjusted for year of di-
agnosis and were from a multivariate logistic regression
model that was used to estimate the likelihood of delay
between sign or symptom and diagnosis (Table 3). The
presence of 1 or more comorbidities was strongly predic-
tive of diagnostic delay (odds ratio [OR], 2.83; 95% con-
fidence interval [CI], 2.45-3.28). Patients aged 75 years
or older were 45% more likely to experience delay (95%
CI, 1.27-1.65). Females (OR, 1.22; 95% CI, 1.07-1.39)
and urban residents (OR, 1.46; 95% CI, 1.19-1.79) were
also more likely to experience delay. Patients who had
received care in a teaching hospital before CLL diagnosis
were 20% more likely to experience diagnostic delay
(95%CI, 1.05-1.38).
Approximately half (2282) of the study patients had
a claim for flow cytometry at any time during the study
period; 1965 (38.6%) patients had their initial flow
cytometry performed within 30 days before or after the
SEER diagnosis date. The use of flow cytometry increased
significantly over the study period (Fig. 1). (A Cochran-
Armitage test for trend was significant at P < .01. It
should be noted that Medicare initiated a national cover-
age decision for flow cytometry in 2000.) The results
from the logistic regression predicting flow cytometry at
any time during the study period are shown in Table 4
and were also adjusted for year of diagnosis. Significant
predictors of flow cytometry were age younger than 75
years (OR, 1.46; 95% CI, 1.30-1.66), urban residence
(OR, 1.27; 95% CI, 1.05-1.53), and residence in the
Northeast (OR, 2.01; 95% CI, 1.69-2.39) or South (OR,
1.51; 95% CI, 1.22-1.89) when compared with the West
(the Western classification includes the state of Hawaii).
Of note, because of low numbers of cases from some











Age, y, median [IQR] 75 [70-85] 75 [71-81]
Race
White 4702 (92.4) 3758 (92.1)
Black 234 (4.6) 195 (4.8)
Other 150 (3.0) 128 (3.1)
Sex
Men 2751 (54.1) 2128 (52.1)
Women 2335 (45.9) 1953 (47.9)
Urban resident 4400 (86.5) 3534 (86.6)
Modified Charlson score
0 or no claims 3722 (73.2) 2865 (70.2)
1 952 (18.7) 827 (20.3)
2 245 (4.8) 231 (5.7)
3 or more 167 (3.3) 158 (3.8)
Region of residence
Northeast 858 (16.9) 701 (17.2)
South 507 (10.0) 436 (10.7)
Midwest 1522 (29.9) 1262 (30.9)
West 2199 (43.2) 1682 (41.2)
Care in teaching hospitala 2852 (56.1) 2346 (57.5)
IQR indicates Interquartile range.
aWithin the year prior to diagnosis.
Table 2. Presenting Signs, Symptoms, and Diagnostic Tests
Before SEER Diagnosis Datea










Weight loss 152 3.0
Abdominal fullness 71 1.4
Rhinitis 71 1.4
Monoclonal gammopathy 39 0.8
Hepatomegaly 38 0.7
Night sweats 29 0.6
Hypogammaglobulinemia 24 0.5
Bleeding <11 <0.3
Failure to thrive <11 <0.3
Diagnostic procedures
Complete blood count 2868 56.4
Flow cytometry 1026 20.2
Bone marrow biopsy 803 15.8
Lymph node biopsy 107 2.1
aFull Sample (n¼5086).
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registries, we report these results by geographic region of
the United States; however, our parameter estimates did
not change when SEER registries were included as covari-
ates. Finally, an increased number of signs or symptoms
before diagnosis was associated with an increased likeli-
hood of having flow cytometry performed (OR, 1.15;
95% CI, 1.08-1.22). Patients with comorbidities were
less likely to receive flow cytometry (OR, 0.88; 95% CI,
0.76-1.02), but the difference was not statistically
significant.
The median survival time for the full sample was
10.4 years. Patients who survived beyond the end of the
observation period were censored at 5056 days (13.8
years, the end of the study period). The results of the
multivariate Cox regression model are shown in Table 5;
hazard ratios (HR) and 95% confidence intervals are
reported. This model estimated the effect of patient char-
acteristics, as well as processes of care, on overall survival.
Patients diagnosed at the age of 75 years or older, males,
and patients with comorbidities had significantly shorter
survival times. Whereas the receipt of systemic chemo-
therapy within 6 months of diagnosis (HR, 1.58; 95%CI,
1.42-1.77) and history of care in teaching hospitals (HR,
1.23; 95% CI, 1.14-1.34) were also associated with
shorter survival times, patients who had flow cytometry
performed had significantly increased survival times (HR,
0.84; 95% CI, 0.76-0.91). We did not observe a signifi-
cant effect of delay between sign or symptom and diagno-
sis on overall survival (HR, 1.11; 95% CI, 0.99-1.25]). In
the sensitivity analyses described above, the relations
reported were similar when delay was treated as a continu-
ous measure, as a tertile, or as a quartile, as well as when
time from sign or symptom to diagnosis exceeded the
mean (as opposed to the median) for the sample. When
we compared parameter estimates, hazard ratios, and sta-
tistical significance for the dependent variables in a re-esti-
mated Cox model with empirically derived independent
variables, these also did not change appreciably. Although
diagnostic delay remained not significant, an interaction
term between delay and comorbidity was marginally sig-
nificant (OR, 1.21; 95%CI, 1.01-1.44; P¼ .034).
DISCUSSION
We found that older patients, female patients, and
sicker patients were more likely to experience delay in
Table 3. Factors Predicting Likelihood of Diagnostic Delaya











Urban resident 1.46 1.19-1.79
Rural resident - -
Modified Charlson score
1 or more comorbidities 2.83 2.45-3.28






Care in teaching hospitalb 1.20 1.05-1.38
CI indicates confidence interval.
Model additionally adjusted for year of diagnosis (output suppressed),
c-statistic 0.67, Likelihood Ratio v2: 403.5, 20 degrees of freedom (df),
P <.0001.
a n¼4081.
bWithin the year prior to diagnosis.
Figure 1. The use of flow cytometry has increased over the
study period. Delays in diagnosis were least frequent in 1991
and were most frequent in 2000. In 2000, the Center for
Medicare and Medicaid Services issued a national coverage
decision to reimburse for diagnostic flow cytometry. Coch-
ran-Armitage tests for trend were significant for both flow
cytometry and diagnostic delay at P < .0001.
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diagnosis for CLL, a finding similar to our prior study
of Medicare recipients with multiple myeloma.14 As the
presenting signs and symptoms in CLL are often seen
first by primary care providers—and given mounting in-
terest in ‘‘medical homes’’ to provide initial evaluation
and coordination for a majority of patient prob-
lems21—it is increasingly likely that primary care pro-
viders will be responsible for the initial diagnosis of
patients with CLL. The literature on childhood malig-
nancies and adult solid tumors has linked such delays to
both the frequency of patients seen by primary care pro-
viders in clinical practice22-25 and knowledge gaps
regarding screening and diagnosis.24,26 As with those
malignancies, educational and policy initiatives to sup-
port clinicians’ evaluations of hematologic abnormalities
seen in primary care may be required to ensure appro-
priate diagnosis and referral of patients with CLL.
Although we did find that certain clinical and socio-
demographic characteristics were associated with delay,
delay did not impact survival. This is not surprising
because most patients have early stage disease at diagnosis
and do not require therapy for some time. Indeed, 2
randomized trials found that chemotherapy for early stage
CLL slowed disease progression but did not confer a sur-
vival benefit.27 Also expected was our finding that older
age and increased comorbidity were associated with
poorer survival. Our data suggest that for a subset of older
patients with significant health problems, the more effec-
tive therapeutic options for CLL may be initially withheld
by treating clinicians, not well& tolerated when given, or
both.
We observed a significant tendency for men to be
diagnosed quicker than women. Such a gender gap in
CLL diagnostic delay is consistent with that seen in other
conditions such as cardiovascular disease.28-29 Important
gender differences in incidence, stage, and biology of CLL
have also been previously reported.30 Our data support a
complicated picture of diagnostic care for older women
generally and speak to the need for observational cohort
studies to understand whether such differences are due to
Table 4. Factors Predicting Likelihood of Flow Cytometrya











Urban resident 1.27 1.05-1.53
Rural resident - -
Charlson score
1 or more comorbidities 0.88 0.76-1.02






Care in teaching hospitalb 1.12 0.98-1.27
No. of signs or symptomsc 1.15 1.08-1.22
CI indicates confidence interval.
Model additionally adjusted for year of diagnosis (output suppressed), c-
statistic 0.73,
Likelihood Ratio v2: 872.73, 21 df, P < .0001.
a (n¼5086)
bWithin the year prior to diagnosis.
c Before diagnosis.
















Urban resident 0.98 0.88-1.10
Rural resident - -
Region of Residence 0.99 0.96-1.03
Charlson score
1 or more comorbidities 1.49 1.37-1.63
Zero or no claims - -




Systemic chemotherapy administered 1.58 1.42-1.77
Care in teaching hospitala 1.23 1.14-1.34
Flow cytometry performedb 0.84 0.76-0.91
Diagnostic delay present 1.11 0.99-1.25
CI indicates confidence interval.
Model additionally adjusted for year of diagnosis.
a In the year before diagnosis.
b30 days of SEER diagnosis date.
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patient- or provider-related factors. Finally, urban resi-
dents were more likely to experience delays, which might
seem unexpected because urban areas tend to have more
high-quality teaching hospitals. Teaching status, however,
is only modestly associated with delay. Such findings may
be explained in part by increasing evidence that those who
live in rural areas tend to have more consistent sources of
care (as opposed to urban residents),31 which may be criti-
cal for diagnoses of indolent diseases such as CLL.
Our finding that those patients who had flow
cytometry performed early in their diagnosis experienced
an overall survival benefit is provocative. There are several
possible explanations for this observation. First, the physi-
cians caring for those patients who received flow cytome-
try might have been better informed in the diagnosis and
management of CLL and better able to manage or refer
these patients. Second, flow cytometry might not have
been performed for patients deemed poor candidates for
therapy and who were less likely to survive at baseline.
Third, the use of flow cytometry might have excluded
patients who had morphologically similar diseases with a
worse prognosis (eg, those with mantle cell lymphoma),
and those patients with CLL confirmed by flow cytometry
might have received more appropriate (ie, less toxic) ther-
apy than those whose disease was not definitively identi-
fied. Despite explanation, our data support the routine
use of flow cytometry for diagnosis of CLL as suggested in
current national clinical guidelines. Our findings also pro-
vide external validity to proposals to assess flow cytometry
performance in CLL as a quality of care performance
measure.
Our study has limitations. First, we did not have
data on patient experiences and actual clinical encounters;
chart reviews or interviews with patients and providers
would have enriched our findings. Second, we were not
able to capture CLL diagnoses that were not reported to
cancer registries, a well known issue with population-
based studies of CLL.32 Although cancer registries rou-
tinely receive case reports from hospitals and pathologists,
when a diagnosis is based on a complete blood count in a
private physician’s office, it is less likely to be directly
reported to a cancer registry.10,32 Third, the availability of
only the month (vs the actual date) of SEER-reported
CLL diagnosis is clearly a limitation of our data source;
however, we did perform sensitivity analyses keeping the
original definition of delay but moving individual patient
diagnosis dates up or back by 30 days and did not find
appreciable differences in our results. Fourth, our study
was restricted to traditional Medicare enrollees who
resided in SEER registry areas and did not participate in
managed care plans. Despite including the diagnostic ex-
perience of a large number of older adult patients with
CLL, these factors limit the representativeness of the sam-
ple and the generalizability of our findings. Data augmen-
tation from other registries, such as the CDC’s National
Program of Cancer Registries, would have expanded our
population coverage.
In summary, although we did not see evidence of a
relation between diagnostic delay and survival for patients
with CLL, we did observe significant associations between
delay and patient characteristics such as age, sex, area of
residence, and clinical complexity. In addition, certain
patient characteristics made receipt of baseline flow
cytometry more likely, and the use of flow cytometry was
associated with improved survival. Our data suggest that
diagnostic flow cytometry is an appropriate measure of
the quality of diagnostic care for patients with CLL. Espe-
cially given our finding that its use is increasing, an impor-
tant next step would be to assess its cost effectiveness.
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